Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved 2024-03-21 19:47
Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development 2024-03-04 21:28
First International Shipment of HANSIZHUANG Launched 2024-01-25 21:41
HANSIZHUANG Sets Sail in Indonesia Market 2023-12-28 21:51
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA 2023-12-12 20:30
Henlius Announces NMPA Approvals of Two ADC Candidates for IND 2023-10-27 20:16
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India 2023-10-27 19:47
Henlius Deepens Collaboration with Intas to bring Henlius' Novel anti-PD-1 mAb Serplulimab to Europe and India 2023-10-27 19:13
Henlius 2023 H1 Results: Achieved record profits and RMB2.5 billion revenues, opening a new chapter of high-quality growth 2023-08-25 19:26
Henlius 2022 Annual Results: Significant Achievements in Commercialisation, Surged to RMB3.2 Billion in Revenues 2023-04-01 00:06
EMA Validates Marketing Authorization Application for Henlius' HANSIZHUANG (Serplulimab) 2023-03-24 08:00
First Patient dosed in a Head-to-Head First-Line Bridging Study of HANSIZHUANG for ES-SCLC treatment in the US 2022-11-30 08:00
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Receives NMPA Approval for the Treatment of sqNSCLC 2022-11-01 21:32
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies 2022-06-28 21:50
Henlius' Serplulimab Granted Orphan-Drug Designation in the United States for Small Cell Lung Cancer 2022-04-07 22:21
Henlius Receives NMPA Approval for its First Innovative Monoclonal Antibody HANSIZHUANG 2022-03-25 21:24
Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma 2022-03-17 08:00
Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma 2022-03-16 23:46
Henlius' anti-PD-1 mAb MRCT achieved 15.38 months OS in first-line treatment of SCLC, reducing the risk of death by 38% of the overall population 2021-12-20 22:00
Henlius' 4th Biologics: Bevacizumab Biosimilar Hanbeitai Approved by National Medical Products Administration 2021-12-04 01:51
1 2